Minimally Invasive Procedure, Available in Arizona, Relieves Foot Pain and Improves Quality of Life

PHOENIX - June 19, 2013 - PRLog -- http://www.hyprocure.com – A procedure to correct recurrent or partial talotarsal dislocation (RTTD), a common condition that can produce painful symptoms, side effects and associated secondary conditions throughout the body, is being offered by Foot and Ankle Specialists in Arizona.

In a recent study published in the Journal of Foot & Ankle Surgery, the HyProCure implant -- a small, titanium stent developed to address a partial dislocation of the ankle bone on the heel bone -- results in substantial improvement in foot pain and foot function.

Additionally, patients diagnosed with said secondary conditions, such as plantar fasciitis, bunions and hammertoes, had been relieved of these symptoms without additional surgery. To review the prospective study summary please visit http://hyprocure.com/publications/press/.

Dr. Ryan Hall, Foot and Ankle Specialist from Lakeside, Arizona, is a Master in the HyProCure procedure. “I am seeing mostly favorable results. I have had a generally positive response and follow up from patients with symptomatic tarsal joint instability,” shares Dr. Hall. “I caution patients to watch for visible and/ or painful changes in their feet, knees and lower back. This is especially pertinent if they are using custom made orthotics. I believe this procedure is useful and helpful and should be considered in patients who have a flexible "flat foot" who have failed orthotic therapy.”

Nearly a decade after FDA clearance and the formal adoption of a procedural norm, the HyProCure stent has helped thousands to safely and effectively eliminate recurrent foot pain and secondary symptoms associated with the partial dislocation of the ankle bone on the heel bone. The Graham International Implant Institute continues to engage in ongoing research & development, as well as the refinement of physician training in support of one mission and end goal – Feet are the Foundation. HyProCure continues to support surgeons worldwide with comprehensive training and certification programs in support of the correct procedural methodology associated with the HyProCure stent.

About HyProCure:
HyProCure is an internal stabilization device that is placed inside the foot to correct recurrent or partial talotarsal dislocation (RTTD), a common condition that can produce painful symptoms, side effects and associated secondary conditions throughout the body. The displacement of the ankle bone (talus) collapses the sinus tarsi, leading to abnormal weight-distribution resulting in both misalignment and recurrent pain. The HyProCure stent maintains the natural opening of the sinus tarsi, realigning the ankle bone while instantly stabilizing and restoring the foot's normal anatomy - while correcting the mechanics that resulting in imbalance throughout the rest of the body. HyProCure is a minimally invasive corrective solution for RTTD and excessive foot pronation, and the procedure is typically performed under twilight-anesthesia in an outpatient environment. HyProCure is available across the United States and internationally.

About GraMedica:
GraMedica was founded in 2003 and the Graham International Implant Institute was founded in 2004. Both are uniquely committed to the worldwide understanding and treatment of RTTD and the HyProCure procedure as a means to that end as well as other related foot abnormalities.

#        #        #        #
To learn more about HyProCure or foot, ankle, knee, hip and back pain that may be associated with RTTD, visit http://www.hyprocure.com.

Foot surgeons are invited to learn more about the HyProCure procedure at http://www.hyprocuredoctors.com, or find a live surgical training seminar in your area or region.

Press queries should be directed to A.J. Zimmerman, Communications Coordinator at GraMedica via email: azimmerman(at)gramedica(dot)com